Results 1 to 10 of about 17,569 (308)
Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
Pediatric Allergy and Immunology, 2020 The recent SARS‐CoV‐2 pandemic, which has recently affected Italy since February 21, constitutes a threat to normal subjects, as the coronavirus disease‐19 (COVID‐19) can manifest with a broad spectrum of clinical phenotypes ranging from asymptomatic ...
Ciro Paolillo +2 more
exaly +2 more sources
Agammaglobulinemia: from X-linked to Autosomal Forms of Disease
Clinical Reviews in Allergy and Immunology, 2021 Interruptions or alterations in the B cell development pathway can lead to primary B cell immunodeficiency with resultant absence or diminished immunoglobulin production.
Melissa Cardenas-Morales
exaly +2 more sources
X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world
World Allergy Organization Journal, 2019 Background: X-linked agammaglobulinemia is an inherited immunodeficiency recognized since 1952. In spite of seven decades of experience, there is still a limited understanding of regional differences in presentation and complications.
Zeinab Awad El-Sayed +2 more
exaly +4 more sources
Journal of Clinical Immunology, 2022 X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by mutations in the Bruton tyrosine kinase (BTK) gene leading to B lymphocyte deficiency and susceptibility to infection.
Dana O'Toole +2 more
exaly +2 more sources
COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency
Current Opinion in Allergy and Clinical Immunology, 2021 Purpose of review The clinical outcomes from COVID-19 in monogenic causes of predominant antibody deficiency have pivotal implications for our understanding of the antiviral contribution of humoral immunity.
Mark J Ponsford +2 more
exaly +2 more sources
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer [PDF]
, 2004 X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by mutations in Bruton tyrosine kinase (Btk) and characterized by an arrest in early B-cell development, near absence of serum immunoglobulin, and recurrent bacteria infections.
Astrakhan, A. +9 more
core +3 more sources
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia [PDF]
, 2010 Mutations in Bruton's tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood.
OLIVEIRA JÚNIOR, E.B. +4 more
core +4 more sources
Burton's Agammaglobulinemia and COVID-19 [PDF]
Cureus, 2020 During the SARS-CoV-2 global pandemic, many patients who have co-morbid conditions are considered high risk for morbidity and mortality; however, those who are immunodeficient are at higher risk of becoming seriously ill. In this article, we present a 26-year old male with a history of X-linked agammaglobulinemia who presented to the hospital with ...
Justin G Hovey +2 more
openaire +6 more sources
A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA
Journal of Clinical Immunology, 2023 Purpose To understand the natural history and clinical outcomes for patients with X-linked agammaglobulinemia (XLA) in the United States utilizing the United States Immunodeficiency Network (USIDNET) patient registry.
V. Hernandez-Trujillo +10 more
semanticscholar +1 more source